Latest news with #Laboratories
Business Upturn
30-07-2025
- Business
- Business Upturn
Dr. Reddy's Laboratories shares in focus as company sees double-digit sales growth for FY26
Dr. Reddy's Laboratories shares were in the spotlight on Wednesday after the company's management expressed confidence in achieving strong financial growth in FY26. As of 11:24 AM, the shares were trading 0.67% lower at Rs 1,291.10. In a recent update, the company's Chief Financial Officer stated that Dr. Reddy's is aiming for double-digit sales growth and a robust 25% EBITDA margin for the current financial year. Dr. Reddy's Laboratories shares traded in a narrow range today. The stock opened at ₹1,298.10, slightly lower than its previous close of ₹1,299.80. During the session, it touched an intraday low of ₹1,277.70 and a high of ₹1,298.10. Over the past 52 weeks, the stock has seen a low of ₹1,020.00 and a high of ₹1,421.49. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Recorder
24-07-2025
- Business
- Business Recorder
India's equity benchmarks may open higher on UK trade deal, earnings optimism
India's stock benchmarks will likely open marginally higher on Thursday, lifted by robust earnings from Infosys and optimism over a potential free-trade agreement with Britain. The Gift Nifty futures were trading at 25,298 points as of 7:57 a.m. IST, indicating that the Nifty 50 will open above Wednesday's close of 25,219.9. Broader Asian markets opened firm, tracking overnight gains on Wall Street after the U.S. and Japan announced a bilateral trade pact, which fuelled hopes of additional deals and lifted global risk appetite. Expectations that India and UK will sign a free-trade agreement on Thursday during Prime Minister Narendra Modi's visit to Britain further aided sentiment. The deal is expected to reduce tariffs on goods such as textiles, whisky and automobiles, while expanding market access for businesses. 'A risk-on sentiment is prevailing across Asian markets, buoyed by favourable global cues following the announcement of a bilateral trade deal between the U.S. and Japan and supported by optimism surrounding the earnings season,' Bajaj Broking Research said. On the domestic front, Infosys will be in focus after India's second-largest IT services company raised the lower end of its full-year revenue guidance following a better-than-expected June quarter. Investors will also track market reaction to results from Dr Reddy's Laboratories and Tata Consumer Products. Dr Reddy's narrowly missed profit estimates due to pricing pressure and heightened competition in North America, while Tata Consumer posted a weak quarter as elevated tea and coffee prices weighed on margins.
Economic Times
23-07-2025
- Business
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
News18
23-07-2025
- Business
- News18
Dr Reddys profit rises 1 pc to Rs 1,410 cr in Q1
Agency: PTI Last Updated: New Delhi, Jul 23 (PTI) Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to Rs 1,410 crore during the Juen quarter. The Hyderabad-based drug major reported a net profit of Rs 1,392 crore in the year-ago period. Revenue increased to Rs 8,545 crore in he period under review from Rs 7,673 crore a year earlier. 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said. The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted. 'We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said. Shares of the company ended 0.58 per cent up at Rs 1,247.55 apiece on the BSE. PTI MSS TRB Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
7NEWS
19-06-2025
- Health
- 7NEWS
The Future of Ageing Starts Here: SRW's cutting-edge nutraceuticals for energy, mobility, and immune health
Great health starts from within as does beauty and while many of us like to rely on anti-ageing products, it's actually more about what we are putting into our bodies rather than what we are putting on. Science Research Wellness (SRW) Laboratories is a biotechnology company based in New Zealand, committed to changing the way people think about and experience ageing. Through close collaboration with world-leading scientists, SRW develops cutting-edge epigenetic tests and nutraceutical supplements designed to support individuals in ageing well by caring for their cellular health. At the core of SRW's mission is a scientific approach to wellness. Their range of supplements is carefully formulated to support essential biological functions, targeting energy production, joint mobility, and immune resilience. One of SRW's most popular products is their NMN supplement which retails for $92 a bottle, containing 500mg of pure Nicotinamide Mononucleotide per capsule. NMN is a naturally occurring molecule found in all life forms, vital for the body's production of NAD+, a compound essential for cellular energy, DNA repair, and metabolic function. While trace amounts exist in food, SRW's NMN supplement delivers a clinically relevant dose that supports healthy ageing, brain and heart health, and overall vitality. Shoppers have given the NMN supplement, a 4.7-star rating on SRW's website. 'This supplement made me feel great very rapidly,' one impressed shopper wrote. 'It has greatly improved my mood and I have more sustained energy,' a second shopper added. 'The SRW NMN is top quality, it powers me through the entire day,' a third reviewer commented. Another key product in SRW's portfolio is Skl¹ Mobility which retail for $129 a bottle and are designed to promote joint health, flexibility, and strength. As people age, joint mobility can diminish, impacting daily movement and comfort. Skl¹ supports those looking to maintain an active lifestyle, whether it's used as a complement to regular exercise or as part of a broader long-term plan for joint maintenance. SRW also offers Imm¹ Defence, a supplement formulated to support the immune system through periods of recovery, stress, or high exposure to illness. It's particularly beneficial for individuals who are frequently exposed to pathogens, such as parents, travellers, and healthcare workers, as well as for athletes and physically active individuals who rely on strong immune function for training recovery. Beyond their science-backed formulations, SRW Laboratories is also known for its commitment to sustainability and ethical manufacturing. Their supplements are made in GMP-certified facilities to ensure high standards of quality, purity, and potency. SRW holds FernMark accreditation, a government-endorsed symbol of authenticity and a mark of its New Zealand origin. field of cellular health and nutraceuticals.
